KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target-Reference-Cited by-同舟云学术

KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target

Published:2021-07-29 Issue:61 Volume:6 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Wei Yao¹^ORCID,Ren Xiaoxin¹,Galbo Phillip M.¹²^ORCID,Moerdler Scott¹³^ORCID,Wang Hao¹^ORCID,Sica R. Alejandro¹⁴^ORCID,Etemad-Gilbertson Bijan⁵^ORCID,Shi Lei¹^ORCID,Zhu Liqiang¹,Tang Xudong¹^ORCID,Lin Qi¹^ORCID,Peng Mou¹^ORCID,Guan Fangxia¹,Zheng Deyou²⁶^ORCID,Chinai Jordan M.¹^ORCID,Zang Xingxing¹⁴⁷^ORCID

Affiliation:

1. Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

2. Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

3. Department of Pediatrics, Children’s Hospital, Montefiore Medical Center, Bronx, NY 10461, USA.

4. Department of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA.

5. NextPoint Therapeutics Inc., Cambridge, MA 02142, USA.

6. Departments of Neurology and Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

7. Department of Urology, Montefiore Medical Center, Bronx, NY 10461, USA.

Abstract

Blockade of KIR3DL3 is an immunotherapy for human cancers.

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference57 articles.

1. Cancer immunotherapy: harnessing the immune system to battle cancer

2. A guide to cancer immunotherapy: from T cell basic science to clinical practice

3. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

4. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

5. The third group of the B7‐ CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy;Pharmaceutics;2024-08-29

3. Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma;Cancer Immunology, Immunotherapy;2024-08-06

4. Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth;Cancers;2024-08-06

5. Correct stimulation of CD28H arms NK cells against tumor cells;European Journal of Immunology;2024-08-05